Molecule Details
| InChIKey | IOMMMLWIABWRKL-WUTDNEBXSA-N |
|---|---|
| Canonical SMILES | Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.64 |
| Source | BindingDB;ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16250 |
|---|---|
| Drug Name | Nazartinib |
| CAS Number | 1508250-71-2 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations). |
Categories: Alkaloids Antineoplastic Agents Heterocyclic Compounds, Fused-Ring Pyridines Solanaceous Alkaloids
Cross-references: CHEMBL3787344 ChemSpider: 35308229 ZINC: ZINC000210610738
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P00533 | EGFR | Epidermal growth factor receptor | inhibitor | targets |